Doximity, Inc.
NYSE:DOCSMedical - Healthcare Information Services
-$0.09 today
- Market cap
- $5.47B
- Beta
- 1.29
- P/E (TTM)
- 19.2
- EPS (TTM)
- $1.06
Volume 2.27M
Average 3.89M
DOCS Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Doximity, Inc.NYSE: DOCS
Capital Expenditures · Q2 FY2027 · quarter ended Sep 2026
Capital expenditures turns positive
Q2 FY2027 capital expenditures was $0, compared with -$2.37M a year earlier. Trailing-twelve-month capital expenditures was -$4.69M. Over 3 fiscal years it compounded at +13.2% a year.
Context
- Capital expenditures amounted to 1.4% of revenue in FY2026, up 0.2 pp from a year earlier.
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
- FY2026 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly capital expenditures holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$1.17M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2026
- (8.96M) USD
- Year-over-year change
- -37.4%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | (8.96M) | -37.4% |
| FY2025 | 2025-03-31 | (6.53M) | -12.5% |
| FY2024 | 2024-03-31 | (5.8M) | +6.2% |
| FY2023 | 2023-03-31 | (6.18M) | -8.5% |
| FY2022 | 2022-03-31 | (5.7M) | — |
Capital Expenditures vs competitors
How DOCS compares with its peers on the latest reported figures
- DOCS's LTM Sep 2026 capital expenditures of $4.69M is the smallest of the 10 companies compared; the peer median is $274.89M.
- Its year-over-year change of -38.4% is the lowest of 10, against a peer median of +3.8%.
- Capital expenditures amounts to 0.7% of revenue for DOCS, versus a peer median of 3.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $799.1M | +19.9% | +8.0% | 12.9% | |
| LTM Jun 2026 | $457.7M | +23.9% | -8.2% | 3.1% | |
| LTM Jul 2026 | $355.3M | -12.1% | +14.4% | 8.4% | |
| LTM Jun 2026 | $327M | -25.5% | +14.7% | 3.9% | |
| LTM Jun 2026 | $274.89M | +63.5% | +7.0% | 3.3% | |
| LTM Jul 2026 | $69.52M | -14.8% | -5.0% | 2.4% | |
| LTM Sep 2026 | $58.67M | +49.2% | -14.6% | 4.6% | |
| LTM Sep 2026 | $30M | +3.8% | +14.1% | 2.0% | |
| LTM Jul 2026 | $18.51M | -32.2% | -74.5% | 1.4% | |
| LTM Sep 2026 | $4.69M | -38.4% | +13.2% | 0.7% | |
| Peer median (excluding DOCS) | $274.89M | +3.8% | +7.0% | 3.3% | |
Competitors are the stored peer set for DOCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Net Income | 154.78M | 112.82M | 147.58M | 223.19M | 196.05M |
| Depreciation & Amortization | 5.04M | 10.28M | 10.27M | 10.66M | 14.38M |
| Deferred Income Tax | (41.25M) | 13.23M | (8.59M) | (11.59M) | 32.14M |
| Stock-Based Compensation | 31.44M | 47.83M | 51.08M | 72.39M | 121.63M |
| Change in Working Capital | (40.33M) | (21.03M) | (24.52M) | (24.1M) | (45.7M) |
| Accounts Receivables | (31.02M) | (26.24M) | 3.99M | (27.21M) | (16.88M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 8.66M | (195K) | 8.33M | (663K) | 4.27M |
| Other Working Capital | (17.98M) | 5.4M | (36.85M) | 3.77M | (33.09M) |
| Other Non-Cash Items | 16.89M | 16.47M | 8.29M | 2.72M | 7.96M |
| Operating Cash Flow | 126.58M | 179.6M | 184.1M | 273.27M | 326.46M |
| Capital Expenditures | (5.7M) | (6.18M) | (5.8M) | (6.53M) | (8.96M) |
| Acquisitions (Net) | 0 | (53.5M) | 0 | 0 | (26.53M) |
| Purchases of Investments | (1.32B) | (190.56M) | (472.87M) | (675.56M) | (389.16M) |
| Sales of Investments | 681.72M | 190.32M | 509.85M | 652.78M | 571.82M |
| Other Investing Activities | 595K | 0 | (5.65M) | 0 | 0 |
| Investing Cash Flow | (640.57M) | (59.92M) | 31.19M | (29.3M) | 147.17M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 553.91M | 0 | 0 | 23.3M | 13.68M |
| Common Stock Repurchased | (2.7M) | (85.32M) | (280.72M) | (120.29M) | (431.65M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 9.21M | 10.86M | 4.19M | (34.15M) | (46.09M) |
| Financing Cash Flow | 560.42M | (74.46M) | (276.52M) | (131.14M) | (464.06M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 46.42M | 45.22M | (61.24M) | 112.83M | 9.56M |
| Free Cash Flow | 120.88M | 173.42M | 178.3M | 266.74M | 317.5M |
Doximity, Inc.
NYSE:DOCS
Intrinsic Alpha fair value
Locked
Current Price
$30.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.